Bicara Therapeutics receives 'buy' ratings from TD Cowen and Stifel Nicolaus with a $47 price target.

Bicara Therapeutics, a clinical-stage biopharmaceutical firm focused on bifunctional therapies for solid tumors, has received 'buy' ratings and a $47 price target from TD Cowen and Stifel Nicolaus. The stock opened at $19.00. Major shareholders, including Ra Capital Management and James E. Flynn, have recently purchased significant shares. The company's lead program is ficerafusp alfa, designed to treat solid tumors.

October 11, 2024
4 Articles